2023
Valemetostat for Relapsed or Refractory Peripheral T-Cell Lymphomas: Primary Results from a Phase 1 Trial
Jacobsen E, Maruyama D, Porcu P, Tobinai K, Allen P, Ishitsuka K, Tsukasaki K, Kusumoto S, Foss F, Yamauchi N, Morishima S, Imaizumi Y, Izutsu K, Feldman T, Kawamata T, Kakurai Y, Yamauchi H, Biserna N, Inoue A, Tsutsumi S, Horwitz S. Valemetostat for Relapsed or Refractory Peripheral T-Cell Lymphomas: Primary Results from a Phase 1 Trial. Blood 2023, 142: 303. DOI: 10.1182/blood-2023-172512.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaAdult T-cell leukemia/lymphomaT-cell non-Hodgkin lymphomaObjective response rateDuration of responseProgression-free survivalT-cell lymphomaMedian DORATLL groupPTCL groupData cutoffAdverse eventsClinical activityResponse rateRefractory peripheral T-cell lymphomaMedian progression-free survivalAngioimmunoblastic T-cell lymphomaT-cell leukemia/lymphomaDose-expansion cohortsDose-expansion phaseMedian prior therapiesPreliminary efficacy assessmentComplete response rateDose-escalation phasePhase 2 trial
2018
Duvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical activity in indolent non‐Hodgkin lymphoma in a phase 1 study
Flinn IW, Patel M, Oki Y, Horwitz S, Foss FF, Allen K, Douglas M, Stern H, Sweeney J, Kharidia J, Kelly P, Kelly VM, Kahl B. Duvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical activity in indolent non‐Hodgkin lymphoma in a phase 1 study. American Journal Of Hematology 2018, 93: 1311-1317. PMID: 30033575, PMCID: PMC6220789, DOI: 10.1002/ajh.25228.Peer-Reviewed Original ResearchConceptsIndolent non-Hodgkin lymphomaDose-limiting toxicityNon-Hodgkin lymphomaClinical activityINHL patientsHematologic malignanciesClinical developmentGrade 3 transaminase elevationMedian progression-free survivalOral dual inhibitorAcute respiratory failureE. coli sepsisElevated liver enzymesOpen-label studyAcceptable safety profileAdvanced hematologic malignanciesDose-escalation phaseGrade 3 rashProgression-free survivalSevere adverse eventsPhase 1 studyDuration of responseFavorable clinical activityFurther clinical developmentBID cohortClinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate
Foss FM, Parker TL, Girardi M, Li A. Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate. Clinical Lymphoma Myeloma & Leukemia 2018, 18: e445-e447. PMID: 30181105, DOI: 10.1016/j.clml.2018.06.020.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaClinical activityVarying DosesPralatrexatePatientsLymphomaDoses
2006
Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia.
Choi J, Foss F. Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia. The Yale Journal Of Biology And Medicine 2006, 79: 169-72. PMID: 17940627, PMCID: PMC1994805.Peer-Reviewed Original ResearchMeSH KeywordsAdenine NucleotidesAdultArabinonucleosidesBone Marrow NeoplasmsClinical Trials as TopicClofarabineDrug Administration ScheduleDrug Resistance, NeoplasmHumansImmunophenotypingLeukemia-Lymphoma, Adult T-CellMaleRecurrenceSkin NeoplasmsStem Cell TransplantationTransplantation, HomologousTreatment OutcomeConceptsLow dose clofarabineLymphoblastic leukemiaAllogeneic stem cell transplantationSignificant clinical activityStem cell transplantationNear complete responseAcute lymphoblastic leukemiaPediatric B-ALLT-cell leukemiaAllogeneic transplantsComplete responsePoor prognosisCell transplantationB-ALLPrecursor TClinical activityNew agentsNovel nucleoside analogueClofarabinePatientsLeukemiaNucleoside analoguesSignificant activityRemissionTransplantationImmunomodulatory Effects of Rexinoids
Foss F. Immunomodulatory Effects of Rexinoids. Seminars In Oncology 2006, 33: 21-25. PMID: 16516672, DOI: 10.1053/j.seminoncol.2005.12.019.Peer-Reviewed Original ResearchConceptsImmunomodulatory effectsCutaneous T-cell lymphomaReceptor-targeted therapyImproved clinical outcomesT-cell lymphomaPractical clinical approachExtracorporeal photophoresisClinical outcomesDenileukin diftitoxTherapy optionsHematologic malignanciesClinical activityPharmacotherapeutic agentsLymphoid malignanciesClinical approachTumor cellsRexinoidsMalignancyTreatmentDiftitoxLymphomaTherapy
2005
Activity of Gallium Nitrate in Refractory Peripheral T-Cell Lymphoma
Huang Z, Higgins B, Foss F. Activity of Gallium Nitrate in Refractory Peripheral T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2005, 6: 43-45. PMID: 15989706, DOI: 10.3816/clm.2005.n.026.Peer-Reviewed Original Research
2002
Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox
Gorgun G, Foss F. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox. Blood 2002, 100: 1399-1403. PMID: 12149223, DOI: 10.1182/blood-2002-01-0300.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicAlitretinoinAntineoplastic AgentsB-LymphocytesBexaroteneDiphtheria ToxinGene Expression RegulationHumansInterleukin-2Leukemia-Lymphoma, Adult T-CellLeukemia, Lymphocytic, Chronic, B-CellPrecursor B-Cell Lymphoblastic Leukemia-LymphomaReceptors, Interleukin-2Receptors, Retinoic AcidRecombinant Fusion ProteinsRetinoid X ReceptorsRetinoidsT-LymphocytesTetrahydronaphthalenesTranscription FactorsTretinoinTumor Cells, CulturedConceptsRetinoic acid receptorsImmunomodulatory effectsIL-2RHigh affinity IL-2R expressionCutaneous T-cell lymphomaHigh affinity IL-2R.Interleukin-2 receptor expressionIL-2R expressionT-cell lymphomaB cell leukemia cellsB-cell leukemiaT-cell leukemiaMechanism of actionAutoimmune diseasesHematologic malignanciesClinical activityReceptor expressionLymphoid malignanciesIL-2R.Retinoid X receptor (RXR) familyP75 subunitAcid receptorsRexinoid receptorsLeukemia cellsRexinoids